Introduction: Nanotechnology has revolutionized our approach to medical diagnostics as well as therapeutics and has spanned an entirely new branch of research. This review addresses the potential applications of Nanotechnology in Urology. This article is based on the Dr. Sitharaman Best Essay award of the Urological Society of India for 2016.
Methods: A PubMed search was performed for all relevant articles using the terms, "nanotechnology, nanoparticles, nanoshells, nanoscaffolds, and nanofibers."
Results: The developments in diagnostics include novel techniques of imaging of genitourinary malignancies, prostate-specific antigen measurement, early detection of mutations that are diagnostic for polycystic kidney disease. The potential applications of nanotechnology are in the targeted therapy of genitourinary malignancies, erectile dysfunction, overactive bladder, bladder reconstruction, construction of artificial kidneys and biodegradable stents as well as in robotic surgery.
Conclusions: Nanotechnology is a rapidly emerging branch of research in urology with diverse and clinically significant applications in diagnostics as well as therapeutics.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264185 | PMC |
| http://dx.doi.org/10.4103/0970-1591.194780 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HIF1α Plays a Crucial Role in the Development of TFE3-Rearranged Renal Cell Carcinoma by Orchestrating a Metabolic Shift Toward Fatty Acid Synthesis.
Genes Cells
January 2025
Department of Urology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Tumor development often requires cellular adaptation to a unique, high metabolic state; however, the molecular mechanisms that drive such metabolic changes in TFE3-rearranged renal cell carcinoma (TFE3-RCC) remain poorly understood. TFE3-RCC, a rare subtype of RCC, is defined by the formation of chimeric proteins involving the transcription factor TFE3. In this study, we analyzed cell lines and genetically engineered mice, demonstrating that the expression of the chimeric protein PRCC-TFE3 induced a hypoxia-related signature by transcriptionally upregulating HIF1α and HIF2α.
View Article and Find Full Text PDFRNA nanotherapeutics for hepatocellular carcinoma treatment.
Theranostics
January 2025
Center for Nanomedicine and Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, particularly due to the limited effectiveness of current therapeutic options for advanced-stage disease. The efficacy of traditional treatments is often compromised by the intricate liver microenvironment and the inherent heterogeneity. RNA-based therapeutics offer a promising alternative, utilizing the innovative approach of targeting aberrant molecular pathways and modulating the tumor microenvironment.
View Article and Find Full Text PDFTumor microenvironment-mimicking macrophage nanovesicles as a targeted therapy platform for colorectal cancer.
Int J Pharm
January 2025
General Surgery 3, Department of Surgery, Oncology and Gastroenterology, University of Padova, via Giustiniani 2, 35128 Padua, Italy; NanoInspired Biomedicine Lab, Fondazione Istituto di Ricerca Pediatrica Città della Speranza, Padua, Italy.
Article Synopsis
- Macrophages play a crucial role in the immune response within the tumor environment of colorectal cancer (CRC), and their unique properties can be harnessed to create targeted nanoparticles for treatment.
- Lipid nanovesicles (LNVs) were developed using membrane proteins from differentiated THP-1 cells, resulting in two types: T-LNVs and M1-LNVs, both loaded with the cancer drug doxorubicin (DOXO).
- M1-LNVs demonstrated greater effectiveness in targeting and killing cancer cells compared to T-LNVs, showing promise for precision medicine in cancer therapy with reduced side effects.
Cell-free biodegradable electroactive scaffold for urinary bladder tissue regeneration.
Nat Commun
January 2025
Department of Biomedical Engineering, Northwestern University, Evanston, IL, USA.
Tissue engineering heavily relies on cell-seeded scaffolds to support the complex biological and mechanical requirements of a target organ. However, in addition to safety and efficacy, translation of tissue engineering technology will depend on manufacturability, affordability, and ease of adoption. Therefore, there is a need to develop scalable biomaterial scaffolds with sufficient bioactivity to eliminate the need for exogenous cell seeding.
View Article and Find Full Text PDFThe molecular code of kidney cancer: A path of discovery for gene mutation and precision therapy.
Mol Aspects Med
January 2025
Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, 116011, China. Electronic address:
Renal cell carcinoma (RCC) is a malignant tumor with highly heterogeneous and complex molecular mechanisms. Through systematic analysis of TCGA, COSMIC and other databases, 24 mutated genes closely related to RCC were screened, including VHL, PBRM1, BAP1 and SETD2, which play key roles in signaling pathway transduction, chromatin remodeling and DNA repair. The PI3K/AKT/mTOR signaling pathway is particularly important in the pathogenesis of RCC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!